RAB11B and neoplasm: The results showed that the following factors had a statistically significant impact on the response to conversion therapy efficacy: (1) the longer interval between the last chemotherapy and surgery (CST), the higher the probability of low or no response (OR = 1.046, 95% CI 1.013–1.081, p = 0.006); (2) the tumor invasion of ypT3-4 increasing the risk of low or no response to conversion therapy (OR = 32.096, 95% CI 5.091–202.349, p < 0.001); and (3) distant metastasis (M1) affecting the patients’ response to conversion therapy (OR = 7.050, 95% CI 1.888–26.323, p = 0.004) (Table 9).